Posted by Michael Wonder on 11 Jun 2025
FDA approves taletrectinib for ROS1 positive non-small cell lung cancer
11 June 2025 - Today, the FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1 positive non-small cell lung cancer.
Efficacy was evaluated in patients with locally advanced or metastatic, ROS1 positive non-small cell lung cancer enrolled in two multi-center, single-arm, open-label clinical trials, TRUST-I and TRUST-II.
